1 2 3	Effect of Lymphocyte miRNA Expression on Influenza Vaccine-Induced Immunity
4	Iana H. Haralambieva ¹ , Tamar Ratishvili ¹ , Krista M. Goergen ² , Diane E. Grill ² , Whitney L.
5	Simon ¹ , Jun Chen ² , Inna G. Ovsyannikova ¹ , Gregory A. Poland ¹ , Richard B. Kennedy ¹
6	¹ Mayo Clinic Vaccine Research Group, ² Department of Quantitative Health Sciences, Mayo
7	Clinic, Rochester, MN 55905, USA
8	
9	Running Head: Lymphocyte miRNA Expression and Influenza Vaccine-Induced Immunity
10	Keywords: Influenza Vaccine; Immunity; MicroRNA Expression, T Cells, B Cells, NK Cells
11	
12	
13	Abstract Word Count: 207
14	Word Count: 3,857
15	
16	
17	
18	Address correspondence to:
19	Richard B. Kennedy, Ph.D., Co-Director, Mayo Vaccine Research Group, Mayo Clinic,
20	Guggenheim 611D, 200 First Street SW, Rochester, Minnesota 55905
21	Phone: (507) 284-0708; Fax: (507) 266-4716; Email: <u>kennedy.rick@mayo.edu</u>
22	
23	©Copyright 2024 Mayo Foundation for Medical Education and Research
24	

25 Highlights

26	• Host miRNA expression is relatively stable before and after influenza vaccination						
27	• miR-150-3p, miR-629-5p and miR-4443 were correlated with immunity across cell types						
28	• Specific CD4 ⁺ T cell miRNAs are predictive of antibody responses						
29	• Identified miRNAs may serve as biomarkers of immune response after influenza vaccine						
30	Abstract						
31	Alterations of gene expression by miRNAs contribute substantially to genetic regulation and						
32	cellular functions.						
33	We conducted a comprehensive study in 53 individuals before and after the administration of the						
34	2010-2011 seasonal inactivated influenza vaccine to characterize lymphocyte-specific miRNA						
35	expression (in purified B cells, CD4+ T cells, CD8+ T cells and NK cells) and its effect on						
36	influenza vaccine-induced immune outcomes (hemagglutination inhibition antibody titers/HAI,						
37	viral neutralizing antibody titers /VNA and memory B cell ELISPOT).						
38	Overall, we observed relatively stable miRNA expression before/after influenza vaccination. Our						
39	statistical analysis uncovered three baseline miRNAs (miR-150-3p, miR-629-5p and miR-4443)						
40	that were significantly correlated with influenza vaccine-induced immune outcomes in different						
41	cell types. Predictive modeling of influenza vaccine-induced HAI/VNA titers identified a set of						
42	specific baseline miRNAs in CD4 ⁺ T cells as factors predictive of antibody responses. A						
43	pathway enrichment analysis on the putative target genes revealed several regulated signaling						
44	pathways and functions: TGF- β signaling, PI3K-Akt signaling, p53 signaling, MAPK signaling,						
45	TNF signaling and C-type lectin receptor signaling, as well as cell adhesion and adherens						
46	junctions, and antiviral host response.						

- 47 In conclusion, our study offers evidence for the role of epigenetic modification (miRNAs) on
- 48 influenza vaccine-induced immunity. After validation, identified miRNAs may serve as potential
- 49 biomarkers of immune response after influenza vaccination.

50

52 Introduction

Influenza virus is a pathogen of major public health concern. Seasonal outbreaks can involve 53 millions of cases in the United States and countless more worldwide. Influenza morbidity and 54 mortality is increased in infants, young children, and the elderly. While the impact of influenza 55 on human health has been ameliorated through the use of vaccination, vaccine efficacy rates vary 56 57 greatly from year to year, indicating a need for the development of improved influenza vaccines, especially in those vulnerable populations. Systems biology studies and high-dimensional 58 platforms are often utilized to comprehensively assess the human transcriptome in order to 59 60 elucidate how protective immunity develops and is maintained after vaccination and to discover potential biomarkers of protective immunity. 61 MicroRNAs (miRNAs) are 21-23 nucleotide sequences that modulate gene expression by 62 binding to the 3' UTR of target mRNAs [1]. They control key biological processes and modulate 63 innate and adaptive antiviral responses. Host miRNAs have also been demonstrated to affect 64 viral gene expression and viral miRNAs have been shown to affect host gene expression [2, 3]. 65 miRNA profiling studies of viral infection have highlighted the important regulatory effect of 66 noncoding RNAs on immune response [2-4]. 67 The goal of the study was to comprehensively assess lymphocyte-specific miRNA expression 68 before and after influenza vaccination and to identify baseline/early miRNA biomarkers 69 70 associated with, and perhaps predictive of, immune response to influenza vaccination. 71

72 Methods

The methods described here are similar or identical to the ones in our previously publishedstudies [5-8].

7	-
1	5

76 *Study subjects*

- A subgroup of 53 people was randomly selected from a previously recruited cohort of 159 older
- adults (50-74 years old, males and females) in good general health [7]. Individuals received the
- 79 2010-2011 trivalent inactivated influenza vaccine. This vaccine contained the
- 80 A/California/7/2009 H1N1-like, A/Perth/16/2009 H3N2-like, and B/Brisbane/60/2008-like
- strains. Blood samples were collected before vaccination (Day 0) and at Day 3 and Day 28 post-
- 82 vaccination. The Mayo Clinic Institutional Review Board approved all study procedures and
- 83 written informed consent was obtained from each participant.
- 84
- 85 *Immunologic Testing*
- 86 Influenza A/California/7/2009/H1N1-specific hemagglutination inhibition (HAI) titers, viral
- 87 microneutralization assay (VNA) titers, and B cell ELISPOTs were performed using serum and
- PBMCs from each subject at each timepoint, as previously described [7, 8].
- 89

90 Cell purification and miRNA isolation

91 Cryopreserved PBMCs were thawed using standard procedures; stained with fluorescently

- 92 labeled antibodies to CD3, CD4, CD8, CD19, and CD56 (BD Biosciences; San Jose, CA); and
- 93 sorted by fluorescence-activated cell sorting using a FACSAria (BD Biosciences; San Jose, CA).
- 94 CD4+ T cells, CD8+ T cells, CD3-CD56+ NK cells, and CD19+ B cells were sorted into cold
- 95 PBS containing 2% fetal bovine serum. Total RNA, including miRNA, was extracted using
- 96 miRNeasy Mini Kits (Qiagen; Valencia, CA) according to the manufacturer's instructions.
- 97

98 Next Generation Sequencing

99	Extracted miRNA quantity and quality were assessed using an Agilent 2100 Bioanalyzer
100	(Agilent; Palo Alto, CA). Illumina TruSeq miRNA library construction and single-end read
101	sequencing on Illumina HiSeq 2000 (Illumina; San Diego, CA) was performed at the Mayo
102	Clinic Advanced Genomics Technology Center as previously described [5, 9, 10] with twelve
103	samples multiplexed per lane. Subjects were randomized prior to library preparation and three
104	subjects, each with four cell types, were allocated to a lane; hence, all lanes were balanced by
105	cell type.
106	Bioinformatics
107	The bioinformatics pipeline has been previously described [5]. The processing of the FASTQ
108	files was done using a comprehensive pre-processing and analytical pipeline (CAP-miRNA)
109	[11] that assesses read quality (FastQC); trims adapter sequences (Cutadapt); and aligns reads for
110	Integrative Genomics Viewer (IGV) viewing and detection of mature, precursor, and novel
111	miRNAs (miRDeep2) [12].
112	
113	Statistical Analysis
114	The primary analysis focused on the association between immune response variables (HAI, VNA
115	and B cell ELISPOT) and the expression of each mature miRNA by cell subset (CD4+ T cell,
116	CD8+ T cell, B cell, and NK cell). In addition, analyses were conducted to examine changes over
117	time in mature miRNA expression within cell subsets. For each cell subset, non-expressed
118	miRNAs (median counts of zero at all timepoints) were removed from further analysis for that

cell subset. In total, 129 B cell, 127 CD4+ T cell, 105 CD8+ T cell, and 103 NK cell samples

120 were carried forward for normalization and analysis. Normalization was done separately for each

cell subset using the trimmed mean of M-values method [13] as implemented in the edgeR 121 package [14] in R. A per cell subset post-normalization filter removed miRNA where the 122 median count at each visit were all less than or equal to 4. All correlation analyses were 123 computed using Spearman's correlation and the normalized values of miRNA expression data. 124 Changes over time in miRNA were compared using Generalized Estimating Equations (GEE) 125 126 [15] to account for the within-subject correlation. Per-miRNA negative binomial GEE models were fit in SAS[©] using miRNA as the response variable and the timepoint as the independent 127 variable. The normalization offset and tagwise dispersion were estimated in edgeR [14]. False 128 129 discovery rate control (BH procedure) was performed to correct for multiple testing and both pvalues and FDR-adjusted p-values or q-values were reported. Multivariable models for each of 130 the immune response variables were created using cross-validated, elastic-net penalized 131 regression models, with the tuning parameter $\alpha = 0.9$ [16]. Models were developed separately for 132 each immune response outcome (HAI, VNA or B-cell ELISPOT); cell subset; and timepoint. 133 The dependent variable in each model was the immune response outcome at Day 28 minus the 134 response at Day 0 (log2 scale), while the normalized miRNA expression values were the 135 independent variables. In order to reduce signal noise, only 25% of the miRNAs with the highest 136 137 variability between subjects were considered in each model. Sex was included in the models as a covariate. The R package "multiMiR" [17] was used to identify genes representing validated 138 targets of miRNAs of interest. Identified target genes were used in the "clusterProfiler" R 139 140 package to identify enriched biological (KEGG) pathways regulated by the miRNAs of interest [18]. Results were reported with gene ratio, which represents the ratio of the input genes that are 141 142 annotated in a term, and FDRs (q-values) of enrichment.

144 **Results**

145

146 *miRNA profiles of lymphocyte subsets*

Cell subset- (CD4+ T cell, CD8+ T cell, B cell, and NK cell) specific miRNA expression 147 demonstrated that, overall, miRNA expression was similar across different cell types and 148 149 relatively stable (for most cell subsets) in response to vaccination. Figure 1A displays the common Day 0 miRNA expression between different cell types (miRNA expression overlap), as 150 well as cell type-specific miRNA expression. Supplementary Fig.1 illustrates a heatmap 151 152 clustering of miRNA expression by cell subset. 683 miRNAs had median counts > 0. Of those 412 miRNAs with a median count > 4 (post-normalization filter), CD4⁺ T cells expressed 358, 153 CD8⁺ T cells expressed 324, NK cells expressed 321, and B cells expressed 301. 62.6% of these 154 155 miRNAs were expressed in all four lymphocytes, while cell type-specific miRNAs were relatively rare (Fig. 1A). Our initial hypothesis was that shared miRNAs would be involved 156 primarily in cytoskeletal activity, cell cycle control, proliferation/apoptosis, and other 157 housekeeping activities, while cell subset-specific miRNAs (Table 1) would reflect each 158 lymphocyte's unique immunologic function. Pathway analysis of the predicted targets of cell 159 160 subset-specific miRNAs, however, indicated that some of the identified pathways were also overlapping consisting of miRNAs predicted to influence general signaling pathways and 161 162 transcriptional programs involved in T cell, NK cell and B cell homeostasis, development, 163 differentiation, trafficking and functional activity: MAPK signaling, p53 signaling, adhesion and adherens junctions, cellular senescence, as well as in macromolecule biosynthesis, metabolism, 164 165 cell-to-cell interactions, endocytosis, cytoskeleton regulation, and anti-viral pathways 166 (Supplementary Fig. 2). Importantly, the analysis identified miRNA target pathways predicted to

influence B and T cell receptor signaling and effector functions: MAPK, mTOR, PI3K-Akt, Ras
signaling (Supplementary Fig. 2).

We also examined the 20 miRNAs with the highest median baseline expression level in each cell
type and found that the highly expressed miRNAs are largely overlapping (Supplementary Table
1). There were 22 miRNAs that were in the top 20 for at least two cell subsets (Supplementary

172 Table 1).

173

174 *miRNA changes over time after vaccination*

175 Overall, miRNA profiles in B cells, CD8+ T cells, and CD4+ T cells were stable and barely

176 changed after influenza vaccination. We did not discover significant expression changes (q < 0.1)

in CD4+ T cells or B cells. In CD8+ T cells, the expression of only six miRNAs (miR-143-3p,

miR-152, miR-196a-5p, miR-548f, miR-9-3p, and miR-9-5p) decreased on Day 28 following

179 influenza vaccination. Interestingly, NK cell miRNA expression was much more dynamic and

180 changes were identified earlier, with 142 miRNAs exhibiting significant expression changes on

181 Day 3 following vaccination (Supplementary Table 2). Pathway analysis of the predicted targets

182 of the top NK cell miRNAs (n=24), indicated the regulation of the following pathways: ErbB

signaling pathway (p=2.38E⁻⁰⁶), Hippo signaling pathway (p=1.98E⁻⁰⁵), Wnt signaling pathway

184 $(p=3.04E^{-05})$, MAPK signaling pathway $(p=7.40E^{-05})$, Ras signaling pathway (p=0.001) and

185 mTOR signaling pathway (p=0.001) among others (data not shown).

186

187 *miRNAs correlated with influenza vaccine response*

188 Since the expression of miRNAs in B and T lymphocytes was stable across timepoints, we first

189 explored if the baseline expression level of multiple miRNAs in each cell type correlated with

190	influenza vaccine-induced (Day 28 – Day 0) HAI response (Fig. 1B, Supplementary Table 3).
191	We identified 39 miRNAs with baseline expression significantly correlated with HAI response
192	(Fig. 1B, p<0.01). Importantly, for nine of the miRNAs (23% of the identified miRNAs), the
193	response correlations were significant across more than one cell subset (Fig.1B at p<0.01). For
194	example, the positive correlation between miR-331-3p expression and HAI was significant for B
195	cells, CD4+ T cells, and NK cells (p<0.01, Supplementary Table 3, Fig.1B), while the miR-331-
196	3p correlation in CD8+ T cells was suggestive (p=0.016, Supplementary Table 3). Our results
197	also indicate a large overlap in the HAI-correlated miRNAs between CD8+ T cells and NK cells
198	(6/14 NK miRNAs also found in CD8+ T cells) (Fig. 1B, Supplementary Table 3). Importantly,
199	the baseline expression levels of three miRNAs – miR-150-3p, miR-4443, and miR-629-5p –
200	were significantly correlated with all three immune outcomes (HAI, VNA, B cell ELISPOT) in
201	one or more cell subsets (Fig. 1C and D), which indicates the importance of these miRNAs in the
202	regulation of influenza-specific humoral immunity. miRNAs correlated with VNA and memory
203	B cell ELISPOT responses are listed in Supplementary Table 3, respectively. Of note, the same
204	14 miRNAs correlated with B cell ELISPOT response in CD4+ T cells were also correlated with
205	B cell ELISPOT response in the CD8+ T cell samples.

206

207 Modeling of influenza vaccine-induced immune outcomes

It is expected that multiple miRNAs work in concert to regulate immune response. Thus, a multivariable model, which jointly models the miRNAs in relation to the immune outcomes, could be a more powerful approach to identify predictive miRNAs compared to the "per miRNA" correlation analysis. Therefore, we next applied elastic net regularized linear regression modeling of immune outcomes as a function of miRNA expression. This joint modeling revealed

213	several sets of miRNAs expressed in the different cell subsets that were collectively associated
214	with and predictive of influenza vaccine-induced response outcomes. Figure 2 illustrates the
215	correlation coefficients for the individual miRNAs baseline expression associated with each
216	model. The top two models from our analysis efforts refer to baseline miRNA expression in
217	CD4 ⁺ T cells correlated with both HAI (Fig. 2A) and VNA (Fig. 2B) responses, with extensive
218	overlap in the identified miRNAs. Similarly, baseline miRNA expression in CD8+ and B cells
219	correlated with VNA response and both models contained miR-4792 and miR-331-3p (Fig. 2C
220	and D). For the two top models (Fig. 2A and B), we performed pathway enrichment analysis (as
221	outlined in Statistical Analysis) on the putative target genes. These results are summarized in
222	Fig. 3 and represent evidence for CD4+ T cell miRNA influence on the following biological
223	processes and signaling pathways impacting immune response: carbohydrate and lipid
224	metabolism, endocytosis and cytoskeleton regulation, cell adhesion and adherens junctions,
225	TGF-β signaling, MAPK signaling, p53 signaling, PI3K-Akt signaling and C-type lectin receptor
226	signaling pathways among others. Our predictive modeling efforts of immune outcomes as a
227	function of miRNAs post-vaccination revealed only a small number of CD4 ⁺ T cell/NK cell
228	miRNAs correlated with influenza-specific memory B cell ELISPOT response or HAI titer
229	(Supplementary Fig. 3A, B and C).

230

231 Discussion

Our study assessed miRNA expression before/after influenza vaccination in four major lymphocyte cell types (CD4+ T cell, CD8+ T cell, B cell, and NK cell) and demonstrated stable miRNA expression profiles over time (with the exception of NK cell miRNAs) and noticeably overlapping miRNAs expressed across different cell types. The interrogation of lymphocyte

subset-specific miRNAs at baseline revealed miRNA control of both common and unique 236 functional pathways. Among the targeted unique pathways are pathways closely involved in 237 functional activity of specific cell types. These include the TGF-beta signaling pathway, 238 apoptosis and the related to cell cycle control/longevity FoxO signaling pathway in CD4+ T 239 cells; the PI3K-Akt signaling pathway important for the B cell development/differentiation in B 240 241 cells; and the Ras signaling cascade, triggered downstream of B cell receptor to regulate B cell survival and function. miRNAs also regulated relatively common pathways linked to metabolism 242 and proliferation, cellular senescence, cell adhesion-related pathways, MAPK signaling, p53 243 244 signaling, as well as endocytosis, cytoskeleton regulation, and anti-viral pathways. It is likely that the common pathways reflect the cellular housekeeping activity, cell cycle progression, 245 cytoskeletal functions and metabolism necessary to support lymphocyte activation, 246 247 differentiation, proliferation, and functional/immune activity. Although we expected to find more pronounced changes in cellular miRNA expression levels -248 across timepoints relative to vaccination (baseline, Day 3, Day 28), we found that miRNAs in B 249 250 cells, CD4+ T cells, and CD8+T cells were relatively stable over time following vaccination. Possible explanations of this observation include: sub-optimal timing of miRNA expression 251 252 assessment following vaccination (i.e., miRNA expression changes were detectable at other timepoints); miRNA expression changes existed in antigen-specific cells and were missed with 253 global miRNA expression assessment; or influenza vaccination did not alter significantly the 254 255 host miRNA expression landscape. Interestingly, NK cells exhibited significant changes in miRNA expression at Day 3 post-vaccination relative to baseline. Several of these NK miRNAs 256 257 have been implicated in biological activities that impact NK cell activity. Expression levels of 258 miR152 changed significantly on Day 3 in NK cells, as well as on Day 28 in CD8+ T cells.

miR152 has been demonstrated to control HLA-G expression and NK cell-mediated cytolytic
activity [19].

Another interesting finding, miR-125b-5p, has been reported to inhibit IRF4, which leads to 261 increased expression of MICA a ligand for the NK cell activating receptor NKG2D [20]. 262 Downregulation of this molecule after vaccination would promote enhanced NK cell activity. 263 264 NK cells are important innate lymphocytes that have innate immune memory and are able to significantly regulate adaptive immune responses after vaccination [21]. For example, NK cell 265 cytolytic activity was demonstrated to affect antigen persistence and/or target responding T cells 266 267 after vaccination [21, 22]. Other NK cell functional activities (secretion of IFNy and expression and activating/inhibitory receptors) have been linked to the stimulation of antigen-presenting 268 cells following vaccination [23]. This suggests that changes in NK cell miRNA expression 269 270 following vaccination can have direct or indirect effect on adaptive immune responses after influenza vaccination. Other miRNAs exhibiting NK cell expression changes include miR126-271 5p, which has been implicated in the macrophage response to LPS [24] and in endothelial cell 272 angiogenesis, [25] and miR148a-3p, which in concert with other miRNAs has been demonstrated 273 to modulate plasma cell differentiation in B cells [26]. miR-339-5p has been shown to regulate 274 275 lymphocyte tissue migration [27, 28] and to control inflammation by inhibiting IKK- β and IKK-276 ε activity [29]. Further investigation will be necessary in order to understand what role, if any, 277 these NK cell miRNAs play in cell activation, proliferation, or immune function. 278 Of great interest to vaccinology is the discovery of miRNAs that may regulate immune response and/or potentially serve as biomarkers of vaccine-induced immunity for inclusion in an 279 immune signature predictive of optimal (or suboptimal) vaccine response. In this study, three 280 281 baseline miRNAs (miR-150-3p, miR-629-5p and miR-4443) were significantly negatively

correlated with all three immune outcomes (HAI titer, VNA titer and memory B cell ELISPOT 282 response) when data from all four cell types were analyzed (Fig. 1C and D). miR-150-3p has 283 previously been reported to regulate key biological processes such as inflammation, apoptotic 284 pathways and cell proliferation [30]. miR-150 overexpression has been found to profoundly 285 impair formation of mature B cells and their functional activity with smaller effect on the 286 287 development of T cells, granulocytes and macrophages [31]. Similarly, in our study, increased miR-150 expression in B cells was negatively correlated (p=0.00038) with memory B cell 288 ELISPOT response after influenza vaccine, likely due to mature B cell suppression/suppression 289 290 of germinal center memory B cell differentiation [32], while the increased expression in T cells (CD4+ and CD8+ T cells) was negatively correlated with the HAI/VNA titer. It was previously 291 established that the intracellular miR-150 expression in T cells (e.g., CD4+ T helper cells) is 292 293 downregulated upon T cell activation to control key genes underlying T cell functions due to its quick extracellular release in exosomes [33, 34]. Importantly, extracellular miR-150 level 294 (corresponding to the level of downregulation of intracellular miR-150 in T cells) has been 295 established as a reliable serum marker of lymphocyte activation (T cell activation) [35]. 296 Moreover, the serum level of miR-150 was found to be elevated in subjects following MF-59-297 298 adjuvanted 2009 influenza A (H1N1) vaccination with higher levels observed in subjects with higher antibody titers [33]. This is corroborated by our finding of negative correlation between 299 the intracellular expression of miR-150 in T cells and influenza vaccine-induced HAI/VNA 300 301 antibody responses. Thus, miR-150 expression emerges as a reliable biomarker of influenza vaccine-induced immunity as identified in a previous study [33] and ascertained by our findings. 302 303 miR-629 has been investigated as a prognostic marker in cancer and has been implicated 304 primarily in the regulation of proliferation, apoptosis, cell migration and alteration of TGF-

beta/Smad signaling (via its target gene TRIM33) [36, 37]. Its expression has not been 305 previously linked to immune response to vaccination/infection as suggested by our findings. 306 miR-4443 has been connected to the regulation of key cellular signaling pathways such as the 307 NF- κ B, TGF- β and the Ras signaling pathways [38]. Increased expression of miR-4443 has been 308 linked to dysfunction in T cells mediated via TNF receptor associated factor 4/TRAF4, and thus 309 310 it is possible that this miRNA negatively impacts humoral immunity by impairing CD4+ T cell function [39]. On the other hand, the Ras GTPases serve as signaling checkpoints in antigen 311 receptors, and Ras signaling (regulated in part by the expression of miR-4443) may play a key 312 313 role in immune cell activation and function by engaging multiple downstream effectors [40, 41]. The Ras signaling pathway downstream of BCR is known to be a critical part of B cell 314 proliferation, differentiation, antigenic activation and functional activity [42]. The Ras-ERK1/2 315 MAPK cascade is also tightly involved in Th2 cell differentiation [43], so it is possible that 316 miRNA expression (miR-4443 and other miRNAs) regulating these signaling pathways may 317 fine-tune critical antigen-driven cellular activities in B and T lymphocytes. 318 Other miRNAs of interest demonstrated significant associations with HAI antibody titer (and 319 not other immune outcomes) after influenza vaccination, but across several cell subsets. For 320 321 example, the baseline expression of miR-331-3p was positively associated with HAI in B cells, CD4+ T cells, and NK cells (Fig. 2). 322 Our predictive modeling efforts of baseline miRNA expression confirmed that indeed miR-323 324 331-3p is an important biomarker of influenza vaccine-induced immunity as it was identified as a positive predictor of HAI/VNA antibody titer in CD4+ T cells, B cells and CD8+ T cells (Fig. 2). 325 326 miR-331-3p has been demonstrated to inhibit proliferation and support apoptosis via regulating 327 the PI3K/Akt and ERK1/2 pathways [44, 45]. It is possible that miR-331-3p expression regulates

cell proliferation in several immune cell types and thus contributes to their functional activities 328 following vaccination. For example, both signaling pathways (altered by the expression of miR-329 331-3p) are key in regulating B cell metabolic activity, proliferation and differentiation upon 330 antigenic stimulation and thus are likely to influence vaccine-induced immunity [46]. miRNAs 331 of the miR-17-92 locus (i.e., miR-17 and miR-18a) in B and T cells (Fig.2) were also identified 332 333 as being associated with post-vaccine HAI titer. These miRNAs play an important role in B cell development, differentiation, survival and regulation of class switching, and thus are intimately 334 involved in B cell functionality [47]. The baseline cell expression of miR-15 and miR-223 was 335 336 found to be associated with post-vaccine HAI titer and/or influenza virus-specific memory B cell ELISPOT response in our study. miR-15 was previously demonstrated to target Bcl2 and to 337 regulate B cell survival, while miR-223 is enriched in the memory B cell compartment and 338 regulates an important transcription factor (LMO2) critical for B cell differentiation, and has 339 been also established as a regulator of activation-induced cytidine deaminase (AID) [48]. AID 340 is an essential enzyme mainly expressed in germinal center B cells that plays a role in somatic 341 hypermutation/antibody diversity and Ig class switching [49]. Thus, both miR-15 and miR-223 342 emerge as plausible regulators of B cell function and biomarkers of influenza. vaccine-induced 343 344 humoral immunity. The expression of miR-34a-5p in CD4+ T cells was identified as a plausible predictor of influenza vaccine-induced antibody response (Fig. 2). The involvement of miR-34a-345 5p in plasma cell differentiation (along with miR-125b-5p and miR-101-3p) has been previously 346 347 demonstrated [26], but its role in regulating T cell functionality is still unclear. Interestingly, the expression of miR-125b-5p has also been identified as a predictor of VNA antibody response in 348 349 both B cells and CD4+ T cells in our study.

350 The top predictive models from our study (Fig. 2A and B) identified specific baseline miRNAs in CD4⁺ T cells as predictors (or factors associated with) of influenza vaccine-induced 351 HAI/VNA antibody responses, with some overlap in the identified miRNAs (for the HAI and the 352 VNA model). Interestingly, models involving miRNA expression post-vaccination resulted in 353 less robust findings (Supplementary Fig. 3). The pathway enrichment analysis on the putative 354 355 target genes regulated by the identified baseline miRNAs revealed the impact of several important signaling pathways in CD4+ T cells in shaping the influenza vaccine-induced 356 immunity. These include TGF-β signaling, PI3K-Akt signaling, MAPK signaling, p53 signaling, 357 358 TNF signaling and C-type lectin receptor signaling pathways. Basic cellular activities and functions (regulated by these miRNAs) were also identified as important and impacting influenza 359 vaccine-induced humoral immunity: cell adhesion and adherens junctions, antiviral host 360 361 response, carbohydrate and lipid metabolism, endocytosis and cytoskeleton regulation. The strengths of our study include the miRNA expression assessment in 4 purified cell subsets 362 (B cells, CD4+ T cells, CD8+ T cells and NK cells) of subjects before/after influenza vaccination 363 and the robust statistical modeling of influenza vaccine-induced immunity. The limitation is the 364 lack of replication of the identified miRNA biomarkers/pathways in an independent cohort. 365 366 Important next steps will be experimental validation of the identified miRNAs: co-expression studies of miRNAs and putative targets to provide experimental proof of specific miRNA-367 368 mRNA interactions; and experiments revealing how miRNAs modulate target protein expression 369 and how this impacts immune response [50]. In conclusion, our study uncovered novel information regarding the complex genetic control of 370 immune pathways, leading to better understanding of immune function regulation. The study 371

- also identified plausible predictive biomarkers of influenza vaccine-induced immune response
- 373 outcomes, that warrant validation in future studies.

374

375 Data availability

- All data is available at ImmPort.org (SDY67).
- 377

378 Acknowledgements

- 379 We would like to thank the subjects who volunteered to participate in our study. The study was
- funded by the National Institute of Allergic and Infectious Diseases of the National Institutes of
- Health (U01 AI 089859/Bioinformatics Approach to Influenza A/H1N1 Vaccine Immune
- Profiling and R01AI132348), the Human Immunology Project Consortium Infrastructure and
- 383 Opportunities Fund, and a grant from the Mayo Clinic Biomarker Discovery program (grant
- 384 C4330915).
- 385 The content is solely the responsibility of the authors and does not necessarily represent the 386 official views of the National Institutes of Health.

387

388 Conflict of Interest

389 Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials

being conducted by Merck Research Laboratories. Dr. Poland provides consultative advice to

391 AiZtech; AstraZeneca; Emergent; GlaxoSmithKline; Invivyd; Johnson & Johnson/Janssen;

392 Medicago; Medscape/WebMD; Merck & Co. Inc.; Moderna; NovaSource/NorthStar Energy;

393 Novavax; Ocugen; Regeneron; Sanofi; Syneos Health; and Valneva. Dr. Poland is an adviser to

the White House and World Health Organization on COVID-19 vaccines and monkeypox,

395	respectively. Drs. Poland and Ovsyannikova hold patents related to vaccinia and measles peptide
396	vaccines. Drs. Kennedy, Poland, and Ovsyannikova hold a patent related to vaccinia peptide
397	vaccines. Drs. Poland, Kennedy, Ovsyannikova, and Haralambieva hold a patent related to the
398	impact of single nucleotide polymorphisms on measles vaccine immunity. Drs. Poland,
399	Kennedy, and Ovsyannikova have received grant funding from ICW Ventures for preclinical
400	studies on a peptide-based COVID-19 vaccine. Dr. Kennedy has received funding from Merck
401	Research Laboratories to study waning immunity to mumps vaccine. Dr. Kennedy also offers
402	consultative advice on vaccine development to Merck & Co. and Sanofi Pasteur. These activities
403	have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in
404	compliance with Mayo Clinic Conflict of Interest policies.
405	
406	
407	
408	
409	
410	
411	
412	
413	
414	
415	
416	
417	

418 Figure Legends

419

420 Fig. 1 Baseline miRNA expression and its influence on humoral immune response outcomes

421 following influenza vaccination

422 A. Venn diagram of miRNAs expressed within each cell type. B. Correlation between baseline

423 miRNA expression and HAI antibody titer following influenza vaccination. Correlation plot

424 illustrating the associations between baseline miRNA and HAI antibody titer (Day 28 -Day0) for

425 each cell subset (CD4+ T cell, CD8+ T cell, B cell, and NK cell) C. Baseline miRNAs

426 significantly correlated with all humoral immune outcomes (change in HAI antibody titer, VNA

427 antibody titer and B cell ELISPOT response) for each cell subset. The color of the correlation

428 represents the direction (red, negatively associated, blue positively associated with the immune

429 outcome). The size of the circle represents the strength of the correlation. The color intensity

430 scale to the right of the figure is a scale for the Spearman's correlations with darker colors


431 indicating stronger correlation. Blank cells indicate that the correlation with the specific miRNA


432 was zero in the associated cell type, and cells with a "?" indicate that the miRNA was not present

433 (not measured) in the cell type. *p <0.01, **p<0.001. **D.** miRNAs significantly correlated with HAI,

434 VNA, and B cell ELISPOT. Correlations are with the immune response deltas (Day28 – Day0).

435 P < 0.01 was used as the cut-off.





Α.

B cells

miRNA (Day 0)	Immune Response	B cell Correlation	B cell p-value	CD4 Correlation	CD4 p-value	CD8 Correlation	CD8 p-value	NK Correlation	NK p-value
	HAI	-0.31	0.049	-0.31	0.048	-0.49	0.0035	-0.59	0.00026
miR-150-3p	VNA	-0.29	0.065	-0.42	0.0063	-0.54	0.0012	-0.59	0.00025
-	B cell ELISPOT	-0.53	0.00038	-0.38	0.015	-0.28	0.11	-0.30	0.083
	HAI	-0.27	0.094	-0.16	0.32	-0.47	0.0054	-0.56	0.00062
hsa-miR-4443	VNA	-0.25	0.12	-0.24	0.13	-0.54	0.0012	-0.54	0.0011
	B cell ELISPOT	-0.44	0.0044	-0.33	0.037	-0.38	0.03	-0.32	0.068
	HAI	-0.11	0.51	-0.35	0.024	-0.54	0.0012	-0.42	0.014
hsa-miR-629-5p	VNA	-0.17	0.3	-0.40	0.0095	-0.62	0.0001	-0.41	0.017
-	B cell ELISPOT	-0.46	0.0025	-0.27	0.091	-0.35	0.048	-0.07	0.7


443 Fig.2 Predictive modeling of baseline miRNA expression on influenza vaccine-induced

444 humoral immune outcomes

- 445 Modeling was performed as described in Statistical Analysis. The baseline CD4+ T cell miRNAs
- 446 predictive of influenza vaccine-induced HAI titer are depicted in **A**. and those predictive of VNA
- titer are depicted in **B**. The baseline B cell miRNAs and CD8+ T cell miRNAs predictive of
- 448 influenza vaccine-induced VNA titer are depicted in C and D, respectively. The standardized
- linear regression coefficients are the estimated change in the response for a one standard
- 450 deviation change in the associated miRNA expression. Positive coefficient values (bars
- 451 extending to the right of the centerpoint of the x-axis) indicate that an increase in the miRNA
- 452 expression is associated with an increase in the immune response outcome, while negative
- 453 coefficient values (bars extending to the left of the centerpoint of the x-axis) indicate that as the

454 miRNA expression increases the immune. response outcome decreases.





457

Fig. 3 Pathway analysis of target genes regulated by baseline CD4+ T cell-specific miRNAs influencing influenza vaccine-induced HAI/VNA antibody titer

- Enrichment pathway analysis performed (see. Statistical Analysis) on the predicted gene targets
 of baseline CD4+ T cell miRNAs associated with A. HAI titer or B. with VNA titer. The bar
 length corresponds to the significance level of enrichment. Only pathways with q<0.0001 are
- 463 included in the graph.




Table 1. Cell type-specific miRNAs

Table 1. Cell Type-Specific miRNAs						
B cells (n=16)	NK cells (n=22)	CD4 T cells (n=34)	CD8 T cells (n=3)			
hsa-miR-1295a	hsa-miR-10a-3p	hsa-let-7e-3p	hsa-miR-199a-5p			
hsa-miR-129-5p	hsa-miR-1908	hsa-let-7g-3p	hsa-miR-584-5p			
hsa-miR-1303	hsa-miR-196b-5p	hsa-miR-1254	hsa-miR-9-3p			
hsa-miR-138-5p	hsa-miR-20b-3p	hsa-miR-125b-2-3p				
hsa-miR-195-3p	hsa-miR-2355-3p	hsa-miR-1261				
hsa-miR-195-5p	hsa-miR-338-3p	hsa-miR-1285-5p				
hsa-miR-3150b-3p	hsa-miR-429	hsa-miR-1299				
hsa-miR-3614-5p	hsa-miR-432-5p	hsa-miR-1976				
hsa-miR-4491	hsa-miR-4489	hsa-miR-296-5p				
hsa-miR-5196-3p	hsa-miR-4665-5p	hsa-miR-34a-5p				
hsa-miR-574-3p	hsa-miR-4755-5p	hsa-miR-365a-3p				
hsa-miR-577	hsa-miR-4772-3p	hsa-miR-365b-3p				
hsa-miR-582-3p	hsa-miR-4772-5p	hsa-miR-3687				
hsa-miR-629-3p	hsa-miR-550a-3-5p	hsa-miR-374b-3p				
hsa-miR-708-3p	hsa-miR-550a-5p	hsa-miR-4536-5p				
hsa-miR-708-5p	hsa-miR-6131	hsa-miR-455-5p				
	hsa-miR-628-5p	hsa-miR-4688				
	hsa-miR-641	hsa-miR-4781-3p				
	hsa-miR-873-3p	hsa-miR-4791				
	hsa-miR-876-3p	hsa-miR-506-3p				
	hsa-miR-92a-2-5p	hsa-miR-508-3p				
	hsa-miR-93-3p	hsa-miR-508-5p				
		hsa-miR-5090				
		hsa-miR-509-3-5p				
		hsa-miR-509-3p				
		hsa-miR-513c-5p				
		hsa-miR-514a-3p				
		hsa-miR-548b-5p				
		hsa-miR-548q				
		hsa-miR-6511a-3p				
		hsa-miR-6511b-3p				
		hsa-miR-659-5p				
		hsa-miR-676-3p				
		hsa-miR-939-5p				



miRNAs with a median count of less than or equal to 4 were not included.

Λ	7	2
-4	1	2

473

474 **References**

- [1] Connerty P, Ahadi A, Hutvagner G. RNA Binding Proteins in the miRNA Pathway. Int J
- 477 Mol Sci. 2015;17.
- 478 [2] Atherton LJ, Jorquera PA, Bakre AA, Tripp RA. Determining Immune and miRNA
- Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types. Front Immunol.
 2019;10:2323.
- 481 [3] Oshiumi H. Circulating Extracellular Vesicles Carry Immune Regulatory miRNAs and
- Regulate Vaccine Efficacy and Local Inflammatory Response After Vaccination. Front
 Immunol. 2021;12:685344.
- 484 [4] Abu-Izneid T, AlHajri N, Ibrahim AM, Javed MN, Salem KM, Pottoo FH, et al. Micro-
- 485 RNAs in the regulation of immune response against SARS CoV-2 and other viral infections. J
 486 Adv Res. 2021;30:133-45.
- [5] Haralambieva IH, Kennedy RB, Simon WL, Goergen KM, Grill DE, Ovsyannikova IG, et al.
- 488 Differential miRNA expression in B cells is associated with inter-individual differences in
- humoral immune response to measles vaccination. PLoS One. 2018;13:e0191812.
- 490 [6] Haralambieva IH, Painter SD, Kennedy RB, Ovsyannikova IG, Lambert ND, Goergen KM,
- 491 et al. The impact of immunosenescence on humoral immune response variation after influenza
- 492 A/H1N1 vaccination in older subjects. PLoS One. 2015;10:e0122282.
- 493 [7] Haralambieva IH, Ovsyannikova IG, Kennedy RB, Zimmermann MT, Grill DE, Oberg AL,
- 494 et al. Transcriptional signatures of influenza A/H1N1-specific IgG memory-like B cell response
 495 in older individuals. Vaccine. 2016;34:3993-4002.
- 496 [8] Kennedy RB, Ovsyannikova IG, Haralambieva IH, Oberg AL, Zimmermann MT, Grill DE,
- 497 et al. Immunosenescence-Related Transcriptomic and Immunologic Changes in Older
- 498 Individuals Following Influenza Vaccination. Front Immunol. 2016;7:450.
- 499 [9] Haralambieva IH, Zimmermann MT, Ovsyannikova IG, Grill DE, Oberg AL, Kennedy RB,
- et al. Whole Transcriptome Profiling Identifies CD93 and Other Plasma Cell Survival Factor
- 501 Genes Associated with Measles-Specific Antibody Response after Vaccination. PLoS One.
 502 2016;11:e0160970.
- 503 [10] Haralambieva IH, Ovsyannikova IG, Kennedy RB, Larrabee BR, Zimmermann MT, Grill
- 504 DE, et al. Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing
- antibody response to measles vaccine. Hum Genet. 2017;136:421-35.
- 506 [11] Sun Z, Evans J, Bhagwate A, Middha S, Bockol M, Yan H, et al. CAP-miRSeq: a
- 507 comprehensive analysis pipeline for microRNA sequencing data. BMC Genomics. 2014;15:423.
- 508 [12] Friedlander MR, Mackowiak SD, Li N, Chen W, Rajewsky N. miRDeep2 accurately
- identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic AcidsRes. 2012;40:37-52.
- 511 [13] Robinson MD, Oshlack A. A scaling normalization method for differential expression
- analysis of RNA-seq data. Genome Biol. 2010;11:R25.
- 513 [14] Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential
- expression analysis of digital gene expression data. Bioinformatics. 2010;26:139-40.

- 515 [15] Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes.
- 516 Biometrics. 1986;42:121-30.
- 517 [16] Hastie TT, Robert; Friedman, Jerome. The Elements of Statistical Learning: Data Mining,
- 518 Inference, and Prediction. Second Edition ed: Springer; 2009.
- 519 [17] Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The multiMiR R
- 520 package and database: integration of microRNA-target interactions along with their disease and
- drug associations. Nucleic Acids Res. 2014;42:e133.
- 522 [18] Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment
- tool for interpreting omics data. Innovation (Camb). 2021;2:100141.
- 524 [19] Manaster I, Goldman-Wohl D, Greenfield C, Nachmani D, Tsukerman P, Hamani Y, et al.
- 525 MiRNA-mediated control of HLA-G expression and function. PLoS One. 2012;7:e33395.
- 526 [20] Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, et al. Inhibition of
- 527 bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and
- sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-
- 529 miR-125b interplay. J Hematol Oncol. 2016;9:134.
- 530 [21] Cox A, Cevik H, Feldman HA, Canaday LM, Lakes N, Waggoner SN. Targeting natural
- killer cells to enhance vaccine responses. Trends Pharmacol Sci. 2021;42:789-801.
- 532 [22] Rydyznski CE, Waggoner SN. Boosting vaccine efficacy the natural (killer) way. Trends
- 533 Immunol. 2015;36:536-46.
- 534 [23] Goodier MR, Riley EM. Regulation of the human NK cell compartment by pathogens and
- vaccines. Clin Transl Immunology. 2021;10:e1244.
- 536 [24] Huang J, Zhu L, Qiu C, Xu X, Zhang L, Ding X, et al. MicroRNA miR-126-5p Enhances
- 537 the Inflammatory Responses of Monocytes to Lipopolysaccharide Stimulation by Suppressing
- 538 Cylindromatosis in Chronic HIV-1 Infection. J Virol. 2017;91.
- [25] Zhou Q, Anderson C, Hanus J, Zhao F, Ma J, Yoshimura A, et al. Strand and Cell Type-
- specific Function of microRNA-126 in Angiogenesis. Mol Ther. 2016;24:1823-35.
- 541 [26] Tsai DY, Hung KH, Lin IY, Su ST, Wu SY, Chung CH, et al. Uncovering MicroRNA
- 542 Regulatory Hubs that Modulate Plasma Cell Differentiation. Sci Rep. 2015;5:17957.
- 543 [27] Shan W, Li J, Bai Y, Lu X. miR-339-5p inhibits migration and invasion in ovarian cancer 544 cell lines by targeting NACC1 and BCL6. Tumour Biol. 2016;37:5203-11.
- [28] Zhou C, Lu Y, Li X. miR-339-3p inhibits proliferation and metastasis of colorectal cancer.
- 546 Oncol Lett. 2015;10:2842-8.
- 547 [29] Zhang Y, Wei G, Di Z, Zhao Q. miR-339-5p inhibits alcohol-induced brain inflammation
- through regulating NF-kappaB pathway. Biochem Biophys Res Commun. 2014;452:450-6.
- [30] Girardi C, De Pitta C, Casara S, Calura E, Romualdi C, Celotti L, et al. Integration analysis
- of microRNA and mRNA expression profiles in human peripheral blood lymphocytes cultured in modeled microgravity. Biomed Res Int. 2014;2014:296747.
- [31] Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in
- 553 mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl
- 554 Acad Sci U S A. 2007;104:7080-5.
- [32] Inoue T. Memory B cell differentiation from germinal centers. Int Immunol. 2023;35:565-70.
- 557 [33] de Candia P, Torri A, Gorletta T, Fedeli M, Bulgheroni E, Cheroni C, et al. Intracellular
- modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation.
- 559 PLoS One. 2013;8:e75348.

- 560 [34] Pagani M, Rossetti G, Panzeri I, de Candia P, Bonnal RJ, Rossi RL, et al. Role of
- 561 microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation. Immunol Rev. 2012;252:92.06
- **562** 2013;253:82-96.
- 563 [35] de Candia P, Torri A, Pagani M, Abrignani S. Serum microRNAs as Biomarkers of Human
- Lymphocyte Activation in Health and Disease. Front Immunol. 2014;5:43.
- 565 [36] Yan H, Li Q, Wu J, Hu W, Jiang J, Shi L, et al. MiR-629 promotes human pancreatic
- cancer progression by targeting FOXO3. Cell Death Dis. 2017;8:e3154.
- 567 [37] Ledoux D, Mereau A, Dauchel MC, Barritault D, Courty J. Distribution of basic fibroblast
- 568 growth factor binding sites in various tissue membrane preparations from adult guinea pig.
- 569 Biochem Biophys Res Commun. 1989;159:290-6.
- [38] Mao Y, Shen J, Wu Y, Wenjing R, Zhu F, Duan S. Aberrant expression of microRNA-4443
 (miR-4443) in human diseases. Bioengineered. 2022;13:14770-9.
- 572 [39] Qi Y, Zhou Y, Chen X, Ye L, Zhang Q, Huang F, et al. MicroRNA-4443 Causes CD4+ T
- 573 Cells Dysfunction by Targeting TNFR-Associated Factor 4 in Graves' Disease. Front Immunol.574 2017;8:1440.
- 575 [40] Sadeghi Shaker M, Rokni M, Mahmoudi M, Farhadi E. Ras family signaling pathway in
- immunopathogenesis of inflammatory rheumatic diseases. Front Immunol. 2023;14:1151246.
- [41] Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci.
 2005;118:843-6.
- 579 [42] McLaurin JD, Weiner OD. Multiple sources of signal amplification within the B-cell
- 580 Ras/MAPK pathway. Mol Biol Cell. 2019;30:1610-20.
- [43] Yamashita M, Shinnakasu R, Asou H, Kimura M, Hasegawa A, Hashimoto K, et al. Ras ERK MAPK cascade regulates GATA3 stability and Th2 differentiation through ubiquitin-
- 583 proteasome pathway. J Biol Chem. 2005;280:29409-19.
- [44] Zhao D, Sui Y, Zheng X. MiR-331-3p inhibits proliferation and promotes apoptosis by
- targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer. Oncol Rep.
 2016;35:1075-82.
- 587 [45] Epis MR, Giles KM, Candy PA, Webster RJ, Leedman PJ. miR-331-3p regulates
- expression of neuropilin-2 in glioblastoma. J Neurooncol. 2014;116:67-75.
- [46] Jellusova J, Rickert RC. The PI3K pathway in B cell metabolism. Crit Rev Biochem MolBiol. 2016;51:359-78.
- 591 [47] Lou Z, Casali P, Xu Z. Regulation of B Cell Differentiation by Intracellular Membrane-
- 592 Associated Proteins and microRNAs: Role in the Antibody Response. Front Immunol.
- 593 2015;6:537.
- 594 [48] Zan H, Casali P. Epigenetics of Peripheral B-Cell Differentiation and the Antibody
- 595 Response. Front Immunol. 2015;6:631.
- 596 [49] Park SR. Activation-induced Cytidine Deaminase in B Cell Immunity and Cancers.
- 597 Immune Netw. 2012;12:230-9.
- 598 [50] Riolo G, Cantara S, Marzocchi C, Ricci C. miRNA Targets: From Prediction Tools to
- 599 Experimental Validation. Methods Protoc. 2020;4.